Lymph Node Counts in Endometrial Cancer Staging
Status: | Completed |
---|---|
Conditions: | Cervical Cancer, Cancer, Endometrial Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | July 2008 |
End Date: | September 2015 |
A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging
The purposes of this study are to determine whether total lymph node count or the percentage
of identified nodes with metastatic disease are influenced by (1) the method of categorizing
tissue specimens or (2) the techniques of pathologic processing following lymphadenectomy.
Patients with newly diagnosed endometrial carcinoma of high risk histologic type or uterine
carcinosarcoma whose risk of LN metastasis exceeds 15% will be enrolled on this study.
Patients will undergo staging to include hysterectomy and selective lymphadenectomy as per
the clinical judgment of the primary Gynecologic Oncologist. Type of hysterectomy and the
extent and distribution of lymphadenectomy is at the discretion of the surgeon. All patients
will be scheduled for surgical staging. Each subject will have lymph nodes harvested on one
side divided into specific basins, and on the contralateral side classified only as "pelvic"
or "aortic". Surgical node specimens in the operating room will be labeled by (1) specific
nodal basins on the randomly determined side as "external iliac", "obturator", "common
iliac", "aortic", or "high aortic" and by (2) "pelvic" versus "aortic" (common iliac nodes
will be considered as part of the "pelvic" specimen) on the contralateral side.
of identified nodes with metastatic disease are influenced by (1) the method of categorizing
tissue specimens or (2) the techniques of pathologic processing following lymphadenectomy.
Patients with newly diagnosed endometrial carcinoma of high risk histologic type or uterine
carcinosarcoma whose risk of LN metastasis exceeds 15% will be enrolled on this study.
Patients will undergo staging to include hysterectomy and selective lymphadenectomy as per
the clinical judgment of the primary Gynecologic Oncologist. Type of hysterectomy and the
extent and distribution of lymphadenectomy is at the discretion of the surgeon. All patients
will be scheduled for surgical staging. Each subject will have lymph nodes harvested on one
side divided into specific basins, and on the contralateral side classified only as "pelvic"
or "aortic". Surgical node specimens in the operating room will be labeled by (1) specific
nodal basins on the randomly determined side as "external iliac", "obturator", "common
iliac", "aortic", or "high aortic" and by (2) "pelvic" versus "aortic" (common iliac nodes
will be considered as part of the "pelvic" specimen) on the contralateral side.
Inclusion Criteria:
- Uterine cancer with one of the following pathologies: serous, clear cell, sarcoma or
grade 3 differentiation
- surgical candidate
Exclusion Criteria:
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials